BioServe Launches 100th Mission

Space Shuttle Atlantis, the STS-37 mission, April 5, 1991(left) and NASA's SpaceX CRS-32 on April 21, 2025 (right)
Media Credit: NASA/SpaceX
Celebrating a Major Milestone: BioServe Space Technologies Launches Its 100th Mission to Low Earth Orbit
May 2, 2025
Earlier this month, SpaceX’s 32nd Commercial Resupply Services mission funded by NASANational Aeronautics and Space Administration delivered a wide array of research investigations to the International Space Station (ISSInternational Space Station). Each experiment—meticulously prepped, packaged, and engineered for the rigors of space—reflects the dedication of the many research teams and partners working to advance science in microgravityThe condition of perceived weightlessness created when an object is in free fall, for example when an object is in orbital motion. Microgravity alters many observable phenomena within the physical and life sciences, allowing scientists to study things in ways not possible on Earth. The International Space Station provides access to a persistent microgravity environment.. Among those contributors is a longtime leader in space-based research: ISS National Lab Commercial Service ProviderImplementation Partners that own and operate commercial facilities for the support of research on the ISS or are developing future facilities. BioServe Space Technologies, which just reached a significant milestone by supporting its 100th mission enabling space research.
From the days of NASA’s Space Shuttle Program to its continued advancement in the space station era, BioServe has been a pillar of the space science community, with its first mission in 1991. Based at the University of Colorado Boulder, the company has helped enable hundreds of investigations across biomedical science, materials research, and technology development—bringing real value to life on Earth through space-based discovery.
BioServe’s expertise in payload integration and flight hardware design has helped scientists from around the world conduct research in microgravity, fueling breakthroughs in everything from drug development to regenerative medicine and more. The company’s legacy is one of enabling innovation and empowering exploration.
The ISS National Lab congratulates the entire BioServe team on this incredible achievement and thanks them for their continued partnership in driving forward the possibilities of research in low Earth orbit(Abbreviation: LEO) The orbit around the Earth that extends up to an altitude of 2,000 km (1,200 miles) from Earth’s surface. The International Space Station’s orbit is in LEO, at an altitude of approximately 250 miles..
Here are a few stories that highlight BioServe’s impactful work:
- Denver 7, ABC
- CU-Boulder Today
- Celestial Cells: Advancing Regenerative Heart Therapies in Space, Upward
- From Viral Villain to Gene Therapy Hero: Assembling 3D Brain Organoids in Space to Advance Precision Neurological Treatments, Upward
- Orbital Oncology: 3D Cell Cultures in Space Reveal the Secret to Killing Cancer Cells on Earth, Upward
- Unlocking the Secrets of the Immune System: How Tissue Chips in Space Could Hold the Key, Upward
- Mending a Broken Heart Using Microgravity: Cardiovascular Progenitor Cells Hold Promise for Regenerative Therapies, Upward
- Building Bones: Testing a New Osteoporosis Therapy With Mice in Microgravity, Upward